NKTR · Nektar Therapeutics
AI read · Neutral
The AI's read
The company has started all 3 planned Phase 3 eczema trials, and its hair-loss trial is on track to start in December. First results are expected in summer 2028, so any benefit remains years away. Its cash and investments increased, but quarterly costs and net losses rose as sales fell. Those signs point in different directions, so this report does not clearly change the outlook.